NovoCure (NVCR) EBIT Growth (3y) (2017 - 2026)
NovoCure (NVCR) EBIT Growth (3y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | -3.76% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 8.39% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 6.17% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 25.88% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 7.13% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 75.54% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 34.83% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | -2.70% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | NovoCure | 2.28 Bn | 1.85 Bn | 142.48 Mn | 44.76% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 44.76% |
| Mar 31, 2026 | -3.82% |
| Dec 31, 2025 | 2.05% |
| Sep 30, 2025 | -13.54% |
| Jun 30, 2025 | -23.21% |
| Mar 31, 2025 | -260.83% |
| Dec 31, 2024 | -39.34% |
| Sep 30, 2024 | -55.40% |
| Jun 30, 2024 | -39.78% |
| Mar 31, 2024 | -678.50% |
| Dec 31, 2023 | -84.47% |
| Sep 30, 2023 | -80.46% |
| Jun 30, 2023 | -125.04% |
| Mar 31, 2023 | -161.20% |
| Dec 31, 2022 | -556.47% |
| Sep 30, 2022 | -103.15% |
| Jun 30, 2022 | -169.92% |
| Mar 31, 2022 | 49.12% |
| Dec 31, 2021 | -39.26% |
| Sep 30, 2021 | -17.69% |